Telmisartan Ameliorates Nephropathy in Metabolic Syndrome by Reducing Leptin Release from Perirenal Adipose Tissue

Hypertension

Volumn 68, Issue 2, 2016, Pages 478-490

  Li, Hao ^a   Li, Min ^a   Liu, Ping ^b   Wang, YaPing ^c   Zhang, Heng ^a   Li, HongBin ^a,e   Yang, ShiFeng ^a   Song, Yan ^a   Yin, YanRong ^a   Gao, Lan ^a   Cheng, Si ^a   Cai, Jun ^d   Tian, Gang ^a,e  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

^c SHAANXI PROVINCIAL PEOPLE S HOSPITAL   (China)

^d FUWAI HOSPITAL   (China)

^e BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

adipocytes; angiotensin converting enzyme 2; leptin; obesity; telmisartan

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR; ANGIOTENSIN[1-7]; CCAAT ENHANCER BINDING PROTEIN ALPHA; CREATININE; CYCLINE; FATTY ACID BINDING PROTEIN 4; FATTY ACID SYNTHASE; GLUCOSE; INTERLEUKIN 6; LEPTIN; LEPTIN RECEPTOR; LEPTIN RECEPTOR OBRB; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MAS RECEPTOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TELMISARTAN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BENZIMIDAZOLE DERIVATIVE; BENZOIC ACID DERIVATIVE; PROTECTIVE AGENT;

ADIPOCYTE; ADIPOGENESIS; ALBUMINURIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL VIABILITY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOKINE RELEASE; ENDOTHELIUM CELL; ENZYME ACTIVATION; GLOMERULUS; GLUCOSE BLOOD LEVEL; HORMONE RELEASE; IN VITRO STUDY; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; KIDNEY DISEASE; KIDNEY FUNCTION; LIPID DIET; LONG TERM CARE; MALE; METABOLIC DISORDER; METABOLIC PARAMETERS; METABOLIC SYNDROME X; NONHUMAN; PERIRENAL FAT; PHENOTYPE; PRIORITY JOURNAL; PROADIPOCYTE; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; RAT; RENAL CORTICAL TISSUE; RENAL PROTECTION; SIGNAL TRANSDUCTION; TRIACYLGLYCEROL BLOOD LEVEL; UPREGULATION; UREA NITROGEN BLOOD LEVEL; ANIMAL; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; KIDNEY DISEASES; METABOLISM; PHYSIOLOGY; SECRETION (PROCESS); WISTAR RAT;

ADIPOGENESIS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BENZIMIDAZOLES; BENZOATES; DISEASE MODELS, ANIMAL; INTRA-ABDOMINAL FAT; KIDNEY DISEASES; LEPTIN; MALE; METABOLIC SYNDROME X; PROTECTIVE AGENTS; RATS; RATS, WISTAR;

EID: 84974666297     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.116.07008     Document Type: Article

References (42)

1. Scaglione R, Di Chiara T, Cariello T, Licata G. Visceral obesity and metabolic syndrome: two faces of the same medal? Intern Emerg Med. 2010;5:111-119. doi: 10.1007/s11739-009-0332-6.
2. Guzik TJ, Marvar PJ, Czesnikiewicz-Guzik M, Korbut R. Perivascular adipose tissue as a messenger of the brain-vessel axis: role in vascular inflammation and dysfunction. J Physiol Pharmacol. 2007;58:591-610.
3. Després JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature. 2006;444:881-887. doi: 10.1038/nature05488.
4. Schroeter MR, Eschholz N, Herzberg S, Jerchel I, Leifheit-Nestler M, Czepluch FS, Chalikias G, Konstantinides S, Schäfer K. Leptin-dependent and leptin-independent paracrine effects of perivascular adipose tissue on neointima formation. Arterioscler Thromb Vasc Biol. 2013;33:980-987. doi: 10.1161/ATVBAHA.113.301393.
5. Wolf G, Chen S, Han DC, Ziyadeh FN. Leptin and renal disease. Am J Kidney Dis. 2002;39:1-11. doi: 10.1053/ajkd.2002.29865.
6. Wang Y, Chen X, Song Y, Caballero B, Cheskin LJ. Association between obesity and kidney disease: a systematic review and meta-analysis. Kidney Int. 2008;73:19-33. doi: 10.1038/sj.ki.5002586.
7. Li H, Wang YP, Zhang LN, Tian G. Perivascular adipose tissue-derived leptin promotes vascular smooth muscle cell phenotypic switching via p38 mitogen-activated protein kinase in metabolic syndrome rats. Exp Biol Med (Maywood). 2014;239:954-965. doi: 10.1177/1535370214527903.
8. Kalupahana NS, Moustaid-Moussa N. The adipose tissue reninangiotensin system and metabolic disorders: a review of molecular mechanisms. Crit Rev Biochem Mol Biol. 2012;47:379-390. doi: 10.3109/10409238.2012.694843.
9. Yvan-Charvet L, Quignard-Boulangé A. Role of adipose tissue reninangiotensin system in metabolic and inflammatory diseases associated with obesity. Kidney Int. 2011;79:162-168. doi: 10.1038/ki.2010.391.
10. Skurk T, van Harmelen V, Blum WF, Hauner H. Angiotensin II promotes leptin production in cultured human fat cells by an ERK1/2-dependent pathway. Obes Res. 2005;13:969-973. doi: 10.1038/oby.2005.113.
11. Ferrario CM. ACE2: more of Ang-(1-7) or less Ang II? Curr Opin Nephrol Hypertens. 2011;20:1-6. doi: 10.1097/MNH.0b013e3283406f57.
12. Than A, Leow MK, Chen P. Control of adipogenesis by the autocrine interplays between angiotensin 1-7/Mas receptor and angiotensin II/AT1 receptor signaling pathways. J Biol Chem. 2013;288:15520-15531. doi: 10.1074/jbc.M113.459792.
13. Sukumaran V, Veeraveedu PT, Gurusamy N, Yamaguchi K, Lakshmanan AP, Ma M, Suzuki K, Kodama M, Watanabe K. Cardioprotective effects of telmisartan against heart failure in rats induced by experimental autoimmune myocarditis through the modulation of angiotensin-converting enzyme-2/angiotensin 1-7/mas receptor axis. Int J Biol Sci. 2011;7:1077-1092.
14. Wang Y, Song Y, Suo M, Jin X, Tian G. Telmisartan prevents high-fat dietinduced hypertension and decreases perirenal fat in rats. J Biomed Res. 2012;26:219-225. doi: 10.7555/JBR.26.20120013.
15. Ali AT, Hochfeld WE, Myburgh R, Pepper MS. Adipocyte and adipogenesis. Eur J Cell Biol. 2013;92:229-236. doi: 10.1016/j.ejcb.2013.06.001.
16. Boothby M, McGee KC, Tomlinson JW, Gathercole LL, McTernan PG, Shojaee-Moradie F, Umpleby AM, Nightingale P, Shahmanesh M. Adipocyte differentiation, mitochondrial gene expression and fat distribution: differences between zidovudine and tenofovir after 6 months. Antivir Ther. 2009;14:1089-1100. doi: 10.3851/IMP1457.
17. Cao H. Adipocytokines in obesity and metabolic disease. J Endocrinol. 2014;220:T47-T59. doi: 10.1530/JOE-13-0339.
18. Simões e Silva AC, Silveira KD, Ferreira AJ, Teixeira MM. ACE2, angiotensin-( 1-7) and Mas receptor axis in inflammation and fibrosis. Br J Pharmacol. 2013;169:477-492. doi: 10.1111/bph.12159.
19. de Luis DA, Conde R, González-Sagrado M, Aller R, Izaola O, Dueñas A, Pérez Castrillón JL, Romero E. Effects of telmisartan vs olmesartan on metabolic parameters, insulin resistance and adipocytokines in hypertensive obese patients. Nutr Hosp. 2010;25:275-279.
20. Bakris G, Burgess E, Weir M, Davidai G, Koval S; AMADEO Study Investigators. Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. Kidney Int. 2008;74:364-369. doi: 10.1038/ki.2008.204.
21. Takeda M, Yamamoto K, Takemura Y, Takeshita H, Hongyo K, Kawai T, Hanasaki-Yamamoto H, Oguro R, Takami Y, Tatara Y, Takeya Y, Sugimoto K, Kamide K, Ohishi M, Rakugi H. Loss of ACE2 exaggerates highcalorie diet-induced insulin resistance by reduction of GLUT4 in mice. Diabetes. 2013;62:223-233. doi: 10.2337/db12-0177.
22. Prasannarong M, Santos FR, Henriksen EJ. ANG-(1-7) reduces ANG II-induced insulin resistance by enhancing Akt phosphorylation via a Mas receptor-dependent mechanism in rat skeletal muscle. Biochem Biophys Res Commun. 2012;426:369-373. doi: 10.1016/j. bbrc.2012.08.093.
23. Schling P, Löffler G. Cross talk between adipose tissue cells: impact on pathophysiology. News Physiol Sci. 2002;17:99-104.
24. Rubio-Ruíz ME, Del Valle-Mondragón L, Castrejón-Tellez V, Carreón-Torres E, Díaz-Díaz E, Guarner-Lans V. Angiotensin II and 1-7 during aging in Metabolic Syndrome rats. Expression of AT1, AT2 and Mas receptors in abdominal white adipose tissue. Peptides. 2014;57:101-108. doi: 10.1016/j.peptides.2014.04.021.
25. Crandall DL, Herzlinger HE, Saunders BD, Kral JG. Developmental aspects of the adipose tissue renin-angiotensin system: therapeutic implications. Drug Dev Res. 1994; 32: 117-125.
26. Kim S, Whelan J, Claycombe K, Reath DB, Moustaid-Moussa N. Angiotensin II increases leptin secretion by 3T3-L1 and human adipocytes via a prostaglandin-independent mechanism. J Nutr. 2002;132:1135-1140.
27. Cassis LA, English VL, Bharadwaj K, Boustany CM. Differential effects of local versus systemic angiotensin II in the regulation of leptin release from adipocytes. Endocrinology. 2004;145:169-174. doi: 10.1210/ en.2003-0767.
28. Yvan-Charvet L, Even P, Bloch-Faure M, Guerre-Millo M, Moustaid-Moussa N, Ferre P, Quignard-Boulange A. Deletion of the angiotensin type 2 receptor (AT2R) reduces adipose cell size and protects from dietinduced obesity and insulin resistance. Diabetes. 2005;54:991-999.
29. Juge-Aubry CE, Henrichot E, Meier CA. Adipose tissue: a regulator of inflammation. Best Pract Res Clin Endocrinol Metab. 2005;19:547-566. doi: 10.1016/j.beem.2005.07.009.
30. Wang P, Xu TY, Guan YF, Su DF, Fan GR, Miao CY. Perivascular adipose tissue-derived visfatin is a vascular smooth muscle cell growth factor: role of nicotinamide mononucleotide. Cardiovasc Res. 2009;81:370-380. doi: 10.1093/cvr/cvn288.
31. Ohmura T, Tsunenari I, Seidler R, Chachin M, Hayashi T, Konomi A, Matsumaru T, Sumida T, Hayashi N, Horie Y. Renoprotective effects of telmisartan on renal injury in obese Zucker rats. Acta Diabetol. 2012;49(suppl 1):S15-S24. doi: 10.1007/s00592-007-0016-5.
32. Wohl P, Krusinová E, Hill M, Kratochvílová S, Zídková K, Kopecký J, Neskudla T, Pravenec M, Klementová M, Vrbíková J, Wohl P, Mlejnek P, Pelikánová T. Effect of telmisartan on selected adipokines, insulin sensitivity, and substrate utilization during insulin-stimulated conditions in patients with metabolic syndrome and impaired fasting glucose. Eur J Endocrinol. 2010;163:573-583. doi: 10.1530/EJE-10-0436.
33. Usui I, Fujisaka S, Yamazaki K, et al. Telmisartan reduced blood pressure and HOMA-IR with increasing plasma leptin level in hypertensive and type 2 diabetic patients. Diabetes Res Clin Pract. 2007;77:210-214. doi: 10.1016/j.diabres.2006.11.014.
34. Derosa G, Cicero AF, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Ferrari I, Gravina A, Fogari R. Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factoralpha. Hypertens Res. 2006;29:849-856. doi: 10.1291/hypres.29.849.
35. Fernández-Galaz C, Fernández-Agulló T, Pérez C, Peralta S, Arribas C, Andrés A, Carrascosa JM, Ros M. Long-term food restriction prevents ageing-associated central leptin resistance in wistar rats. Diabetologia. 2002;45:997-1003. doi: 10.1007/s00125-002-0851-4.
36. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA, Kurtz TW. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgammamodulating activity. Hypertension. 2004;43:993-1002. doi: 10.1161/01. HYP.0000123072.34629.57.
37. Fujisaka S, Usui I, Kanatani Y, et al. Telmisartan improves insulin resistance and modulates adipose tissue macrophage polarization in high-fat-fed mice. Endocrinology. 2011;152:1789-1799. doi: 10.1210/ en.2010-1312.
38. Araki K, Masaki T, Katsuragi I, Tanaka K, Kakuma T, Yoshimatsu H. Telmisartan prevents obesity and increases the expression of uncoupling protein 1 in diet-induced obese mice. Hypertension. 2006;48:51-57. doi: 10.1161/01.HYP.0000225402.69580.1d.
39. Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation. 2004;109:2054-2057. doi: 10.1161/01.CIR. 0000127955.36250.65.
40. Janke J, Schupp M, Engeli S, Gorzelniak K, Boschmann M, Sauma L, Nystrom FH, Jordan J, Luft FC, Sharma AM. Angiotensin type 1 receptor antagonists induce human in-vitro adipogenesis through peroxisome proliferator-activated receptor-gamma activation. J Hypertens. 2006;24:1809-1816. doi: 10.1097/01.hjh.0000242405.68461.84.
41. Shimabukuro M, Tanaka H, Shimabukuro T. Effects of telmisartan on fat distribution in individuals with the metabolic syndrome. J Hypertens. 2007;25:841-848. doi: 10.1097/HJH.0b013e3280287a83.
42. Boccara F, Auclair M, Cohen A, Lefèvre C, Prot M, Bastard JP, Capeau J, Caron-Debarle M. HIV protease inhibitors activate the adipocyte renin angiotensin system. Antivir Ther. 2010;15:363-375. doi: 10.3851/IMP1533.